30 July 2008 Business
Japan’s ministry of health has concluded that studies based on clinical trials for Novartis’s blood pressure drug Diovan contain manipulated data. It is now investigating whether the company has broken Japanese law by citing these studies to promote the product.
Diovan was approved for use in Japan in 2000, but recently two universities who hosted and analysed trials for Novartis – the Kyoto Prefectural University of Medicine and Jikei University School of Medicine – reported finding evidence of data fabrication. In August, the ministry of health launched an investigation, which has led to the retraction of several papers relating to Diovan’s ability to prevent angina and stroke. Some hospitals have stopped offering the drug, and investigations are now underway at three other universities that hosted Diovan clinical trials.
It is not yet clear who is responsible. As the investigation continues, officials at both Novartis HQ in Switzerland and Novartis Pharma KK, the Japanese subsidiary, have pledged their cooperation.
9 December 2013 Research
Researchers invent self-propelled devices that degrade organic pollutants
6 December 2013 Research
Fungi from soil in citizen scientists' gardens have thrown up some potential drug candidates
13 July 2012 Research
Study of meteorite isotope ratios suggests Earth's water was delivered by express asteroid rather than comets